Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma
- 1 January 2002
- journal article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 12 (1) , 86-90
- https://doi.org/10.1053/srao.2002.31380
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumorsInternational Journal of Radiation Oncology*Biology*Physics, 2001
- A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck CancerJournal of Clinical Oncology, 2000
- Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02International Journal of Radiation Oncology*Biology*Physics, 2000
- A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectumDiseases of the Colon & Rectum, 1997
- The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278Cancer Chemotherapy and Pharmacology, 1992
- Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721International Journal of Radiation Oncology*Biology*Physics, 1992
- Final report on phase i trial of WR-2721 before protracted fractionated radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1988
- Radioprotection of tumor and normal tissues by thiophosphate compoundsCancer, 1973
- Cysteine Protection against X IrradiationScience, 1949